$IBIO
iBio, Inc.

2024 Q1 Form 10-Q Financial Statement

#000155837024000934 Filed on February 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.722M $2.961M
YoY Change -22.78% -59.04%
% of Gross Profit
Research & Development $904.0K $1.535M
YoY Change -65.81% -44.76%
% of Gross Profit
Depreciation & Amortization $235.0K $235.0K
YoY Change 21.76% -2.49%
% of Gross Profit
Operating Expenses $3.626M $4.496M
YoY Change -41.22% -57.48%
Operating Profit -$3.626M -$4.496M
YoY Change -41.22% -57.48%
Interest Expense $52.00K $34.00K
YoY Change 48.57% 9.68%
% of Operating Profit
Other Income/Expense, Net $991.0K $8.000K
YoY Change -1000.91% -20.0%
Pretax Income -$2.635M -$4.488M
YoY Change -58.03% -57.51%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.172M -$8.211M
YoY Change -56.51% -75.53%
Net Earnings / Revenue
Basic Earnings Per Share -$0.85 -$4.42
Diluted Earnings Per Share -$0.85 -$4.42
COMMON SHARES
Basic Shares Outstanding 3.484M 28.10M
Diluted Shares Outstanding 3.713M 1.856M

Balance Sheet

Concept 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.302M $2.788M
YoY Change -19.2% -71.03%
Cash & Equivalents $5.302M $2.788M
Short-Term Investments
Other Short-Term Assets $16.73M $16.91M
YoY Change -13.25% -18.97%
Inventory $0.00 $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.14M $19.70M
YoY Change 33.39% -48.48%
LONG-TERM ASSETS
Property, Plant & Equipment $3.726M $3.890M
YoY Change -14.5% -8.36%
Goodwill
YoY Change
Intangibles $5.373M $5.378M
YoY Change -0.37% -0.37%
Long-Term Investments
YoY Change
Other Assets $265.0K $265.0K
YoY Change -91.98% -12.54%
Total Long-Term Assets $14.02M $14.32M
YoY Change -18.96% 5.59%
TOTAL ASSETS
Total Short-Term Assets $36.14M $19.70M
Total Long-Term Assets $14.02M $14.32M
Total Assets $50.15M $34.02M
YoY Change 13.0% -34.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.228M $1.859M
YoY Change -39.0% -53.55%
Accrued Expenses $3.998M $3.757M
YoY Change 4.63% -24.88%
Deferred Revenue $175.0K
YoY Change
Short-Term Debt $12.66M $12.66M
YoY Change -7.63% -20.96%
Long-Term Debt Due $673.0K $453.0K
YoY Change 59.86% 10.22%
Total Short-Term Liabilities $21.43M $21.55M
YoY Change -3.82% -22.4%
LONG-TERM LIABILITIES
Long-Term Debt $1.064M $360.0K
YoY Change -28.88% -80.83%
Other Long-Term Liabilities $2.801M $2.912M
YoY Change -13.15% -12.39%
Total Long-Term Liabilities $3.865M $3.272M
YoY Change -18.13% -37.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.43M $21.55M
Total Long-Term Liabilities $3.865M $3.272M
Total Liabilities $25.29M $24.83M
YoY Change -6.32% -24.72%
SHAREHOLDERS EQUITY
Retained Earnings -$306.1M -$302.9M
YoY Change 8.19% 9.9%
Common Stock $330.9M $312.1M
YoY Change 10.2% 5.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.86M $9.197M
YoY Change
Total Liabilities & Shareholders Equity $50.15M $34.02M
YoY Change 13.0% -34.32%

Cashflow Statement

Concept 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$3.172M -$8.211M
YoY Change -56.51% -75.53%
Depreciation, Depletion And Amortization $235.0K $235.0K
YoY Change 21.76% -2.49%
Cash From Operating Activities -$3.654M -$4.706M
YoY Change -5.63% -38.36%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $1.000M $0.00
YoY Change -87.56% -100.0%
Cash From Investing Activities $1.000M $0.00
YoY Change -87.87% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.025M 4.007M
YoY Change 243.24% -231.64%
NET CHANGE
Cash From Operating Activities -3.654M -4.706M
Cash From Investing Activities 1.000M 0.000
Cash From Financing Activities 5.025M 4.007M
Net Change In Cash 2.371M -699.0K
YoY Change -59.35% -94.14%
FREE CASH FLOW
Cash From Operating Activities -$3.654M -$4.706M
Capital Expenditures $0.00
Free Cash Flow -$4.706M
YoY Change -55.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.42
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-21.54
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.27
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-38.82
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-46.89
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.88
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-72.03
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.42
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-68.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-110.85
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1856000
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
490000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1525000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
466000
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-2.42
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-21.54
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-6.27
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-38.82
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-46.89
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-2.88
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-72.03
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.42
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-68.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-110.85
dei Entity Central Index Key
EntityCentralIndexKey
0001420720
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
false
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1015505
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3243725
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2023Q1 ibio Period For Payment From Issuance Of At Market Facility
PeriodForPaymentFromIssuanceOfAtMarketFacility
P5D
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2022Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35023
dei Entity Registrant Name
EntityRegistrantName
iBio, Inc.
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
285000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
272000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
389000
CY2023Q4 ibio Equipment Financing Payable Current
EquipmentFinancingPayableCurrent
168000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-2797813
dei Entity Address Address Line1
EntityAddressAddressLine1
8800 HSC Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Bryan
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77807-1107
dei City Area Code
CityAreaCode
979
dei Local Phone Number
LocalPhoneNumber
446-0027
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
IBIO
dei Security Exchange Name
SecurityExchangeName
NYSEAMER
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3484266
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2788000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4301000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1057000
CY2023Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
3025000
CY2023Q2 ibio Subscription Receivable Current
SubscriptionReceivableCurrent
204000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
894000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
664000
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
14960000
CY2023Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
18065000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19699000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
26259000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
215000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
253000
CY2023Q4 ibio Convertible Promissory Note Receivable And Accrued Interest
ConvertiblePromissoryNoteReceivableAndAccruedInterest
1750000
CY2023Q2 ibio Convertible Promissory Note Receivable And Accrued Interest
ConvertiblePromissoryNoteReceivableAndAccruedInterest
1706000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
475000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
610000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2565000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2722000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3890000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4219000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5378000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5388000
CY2023Q4 us-gaap Security Deposit
SecurityDeposit
50000
CY2023Q2 us-gaap Security Deposit
SecurityDeposit
50000
CY2023Q4 us-gaap Assets
Assets
34022000
CY2023Q2 us-gaap Assets
Assets
41207000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1859000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1849000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3757000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4034000
CY2023Q2 ibio Equipment Financing Payable Current
EquipmentFinancingPayableCurrent
160000
CY2023Q4 ibio Insurancepremiumfinancingpayable
Insurancepremiumfinancingpayable
481000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
12655000
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
12937000
CY2023Q4 ibio Current Liabilities Related To Assets Held For Sale
CurrentLiabilitiesRelatedToAssetsHeldForSale
1936000
CY2023Q2 ibio Current Liabilities Related To Assets Held For Sale
CurrentLiabilitiesRelatedToAssetsHeldForSale
1941000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21553000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21582000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
205000
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
351000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2912000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3125000
CY2023Q4 ibio Equipment Financing Payable Noncurrent
EquipmentFinancingPayableNoncurrent
155000
CY2023Q2 ibio Equipment Financing Payable Noncurrent
EquipmentFinancingPayableNoncurrent
241000
CY2023Q2 ibio Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
527000
CY2023Q4 us-gaap Liabilities
Liabilities
24825000
CY2023Q2 us-gaap Liabilities
Liabilities
25826000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3243725
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1015505
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
20000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
312064000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
304301000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302897000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288940000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9197000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
15381000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34022000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41207000
us-gaap Revenues
Revenues
50000
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1535000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2779000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3141000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5327000
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2961000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7794000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6508000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12882000
CY2023Q4 us-gaap Operating Expenses
OperatingExpenses
4496000
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
10573000
us-gaap Operating Expenses
OperatingExpenses
9649000
us-gaap Operating Expenses
OperatingExpenses
18209000
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4496000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-10573000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9599000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
466000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15381000
CY2023Q3 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
2896000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
87000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18209000
CY2023Q4 us-gaap Interest Expense
InterestExpense
34000
CY2022Q4 us-gaap Interest Expense
InterestExpense
31000
us-gaap Interest Expense
InterestExpense
60000
us-gaap Interest Expense
InterestExpense
31000
CY2023Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
41000
us-gaap Investment Income Interest
InvestmentIncomeInterest
97000
us-gaap Investment Income Interest
InvestmentIncomeInterest
140000
CY2023Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
37000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
109000
CY2023Q4 ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-4488000
CY2022Q4 ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-10563000
ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-9562000
ibio Net Loss Available To Stockholders From Continuing Operations
NetLossAvailableToStockholdersFromContinuingOperations
-18100000
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3723000
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-22990000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-4395000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33583000
CY2023Q4 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-8211000
CY2022Q4 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-33553000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-13957000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-51683000
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-8211000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-33553000
us-gaap Profit Loss
ProfitLoss
-13957000
us-gaap Profit Loss
ProfitLoss
-51683000
CY2022Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
56000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
46000
CY2023Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8211000
CY2022Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-33497000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13957000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-51637000
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.42
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-21.54
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.27
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-38.82
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-46.89
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.88
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-72.03
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.42
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-68.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-110.85
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1856000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
490000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1525000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
765000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-250000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1134000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-74000
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-21000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
11000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1178000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-354000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1237000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-5746000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
13209000
CY2023Q4 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
4622000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
872000
CY2023Q4 ibio Fractional Share Issued After Reverse Stock Split Value
FractionalShareIssuedAfterReverseStockSplitValue
-7000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
456000
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-8211000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9197000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
63485000
CY2022Q3 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
1151000
CY2022Q3 ibio Common Stock Issued In Rubryc Transaction Value
CommonStockIssuedInRubrycTransactionValue
650000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1222000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-10000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-18130000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
48368000
CY2022Q4 ibio Stock Issued During Period Value Capital Raise
StockIssuedDuringPeriodValueCapitalRaise
3500000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
636000
CY2022Q4 ibio Fractional Share Issued After Reverse Stock Split Value
FractionalShareIssuedAfterReverseStockSplitValue
-39000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1127000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
56000
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-33553000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18823000
us-gaap Profit Loss
ProfitLoss
-13957000
us-gaap Profit Loss
ProfitLoss
-51683000
us-gaap Share Based Compensation
ShareBasedCompensation
1221000
us-gaap Share Based Compensation
ShareBasedCompensation
2349000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
116000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
136000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
88000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
162000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
201000
us-gaap Depreciation
Depreciation
329000
us-gaap Depreciation
Depreciation
388000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
50000
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
ibio Accrued Interest Receivable On Convertible Promissory Note Receivable
AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
44000
ibio Accrued Interest Receivable On Convertible Promissory Note Receivable
AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
38000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
62000
ibio Deferred Financing Costs Amortization Expense
DeferredFinancingCostsAmortizationExpense
120000
ibio Deferred Financing Costs Amortization Expense
DeferredFinancingCostsAmortizationExpense
123000
ibio Increase Decrease In Inventory Reserve
IncreaseDecreaseInInventoryReserve
4933000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
3100000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
17649000
ibio Accrued Payment In Kind Expenses
AccruedPaymentInKindExpenses
-258000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
565000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
5000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-31000
us-gaap Increase Decrease In Finished Goods And Work In Process Inventories
IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
1058000
ibio Increase Decrease In Accrued Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesNoncurrent
-527000
ibio Increase Decrease In Accrued Liabilities Noncurrent
IncreaseDecreaseInAccruedLiabilitiesNoncurrent
1065000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-195000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
30000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10046000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21594000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
4899000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5433000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
50000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
692000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1226000
ibio Proceeds From Issuance Of Preferred And Common Stock
ProceedsFromIssuanceOfPreferredAndCommonStock
7015000
ibio Proceeds From Issuance Of Preferred And Common Stock
ProceedsFromIssuanceOfPreferredAndCommonStock
4015000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
88000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
ibio Payments For Fractional Shares After Reverse Stock Split
PaymentsForFractionalSharesAfterReverseStockSplit
7000
ibio Payments For Fractional Shares After Reverse Stock Split
PaymentsForFractionalSharesAfterReverseStockSplit
39000
ibio Proceeds From Subscriptions Receivable
ProceedsFromSubscriptionsReceivable
204000
ibio Proceeds From Subscriptions Receivable
ProceedsFromSubscriptionsReceivable
0
ibio Proceeds From Equipment Financing Loan
ProceedsFromEquipmentFinancingLoan
500000
ibio Payment Of Equipment Financing Loan
PaymentOfEquipmentFinancingLoan
78000
ibio Payment Of Equipment Financing Loan
PaymentOfEquipmentFinancingLoan
25000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
436000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
6250000
ibio Payments To Attain Term Note
PaymentsToAttainTermNote
22000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
133000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
82000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6477000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1903000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3519000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24723000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7579000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28672000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4060000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3949000
ibio Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
0
ibio Capital Expenditure Incurred For Intangible Assets Paid
CapitalExpenditureIncurredForIntangibleAssetsPaid
1769000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
814000
ibio Increase Decrease In Finance Lease Obligations For New Leases
IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
0
ibio Increase Decrease In Finance Lease Obligations For New Leases
IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
814000
ibio Common Stock Issued In Rubryc Transaction Value
CommonStockIssuedInRubrycTransactionValue
0
ibio Common Stock Issued In Rubryc Transaction Value
CommonStockIssuedInRubrycTransactionValue
650000
ibio Noncashinsurancepremiumfinancingduringperiod
Noncashinsurancepremiumfinancingduringperiod
597000
ibio Noncashinsurancepremiumfinancingduringperiod
Noncashinsurancepremiumfinancingduringperiod
0
ibio Cost To Raise Capital Paid Directly From Gross Proceeds
CostToRaiseCapitalPaidDirectlyFromGrossProceeds
503000
ibio Cost To Raise Capital Paid Directly From Gross Proceeds
CostToRaiseCapitalPaidDirectlyFromGrossProceeds
636000
ibio Coststoraisecapitalincludedinaccruedexpenses
Coststoraisecapitalincludedinaccruedexpenses
369000
ibio Coststoraisecapitalincludedinaccruedexpenses
Coststoraisecapitalincludedinaccruedexpenses
0
ibio Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
0
ibio Unpaid Fixed Assets Included In Accounts Payable
UnpaidFixedAssetsIncludedInAccountsPayable
329000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
46000
us-gaap Interest Paid Net
InterestPaidNet
401000
us-gaap Interest Paid Net
InterestPaidNet
363000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.   Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (the "Company" or “iBio”) is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (“AI”) for the development of precision antibodies. The Company’s proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (“mAb’) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc"). This acquisition commenced the Company’s transition to an AI-enabled biotech company and led to the divestiture of its Contract Development and Manufacturing Organization (“CDMO”) business. This strategic decision allowed the Company to focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of the Company’s technology stack is the patented epitope-steering AI-engine. This advanced technology allows the Company to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile.  Another integral part of the Company’s technology stack is the machine learning (“ML”) based antibody-optimizing StableHu™ technology. When integrated with the Company's mammalian display technology, StableHu has demonstrated its ability to expedite the Lead Optimization process. This integration not only potentially reduces downstream risks but also streamlines the overall development process, making it faster, more efficient, and cost-effective. As a result, optimization can be achieved in less than four weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also developed the EngageTx™ platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (“NHP”) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of the Company’s antibody products. By incorporating EngageTx into the Company’s own development initiatives, the Company’s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to its potential partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recently announced the expansion of its AI-powered technology stack with the launch of ShieldTx™, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By adding ShieldTx to the Company’s technology stack, iBio uniquely integrates antibody engineering and masking in one accelerated process to potentially overcome the challenges of complex targets, safety, and developability in next-generation antibody discovery and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio’s scientific team, composed of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in its San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in-house from concept to in vivo proof-of-concept (“POC’). This multidisciplinary expertise allows the Company to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company’s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. The Company’s core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through the Company’s innovative platform, it champions a culture of innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, with the goal of accelerating preclinical processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the Company’s groundbreaking EngageTx™ technology enables the Company to target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, the Company’s goal is to enhance agility and bolster preclinical safety assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s strategic approach to fulfilling its mission is outlined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Elevate Epitope Discovery:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company believes it leads the field with its patented AI-engine uncovering "hard to develop" molecules. The Company’s unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery.  This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. The Company’s epitope engine is engineered to match its target, refined for stability and optimized for water solubility, allowing the Company to identify new drug candidates that have failed or have been abandoned due to their complexity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capital Efficient Business Approach:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company’s strategic business approach is structured around the following pillars of value creation:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strategic Partnerships</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: The Company is leveraging its platform and pipeline by forming strategic partnerships. The Company’s aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower molecules within the Company’s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into the Company’s platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tech Licensing in Diverse Therapeutic Areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In pursuit of adding value, the Company is exploring partnerships in diverse therapeutic domains such as CNS or vaccines. The Company’s intention is to license the AI tech stack, extending its benefits to the Company’s partners and amplifying its biological impact and insights. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This strategic approach enables the Company to capitalize on the value of its meticulously curated data while empowering collaborations and innovations, while at the same time allowing the Company to focus on both the platform and its core therapeutic area, oncology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Developing and Advancing the Company’s In-house Programs Cost Effectively</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Clinical advancement is crucial for drug discovery. The Company is actively looking for opportunities to progress its internal pre-clinical programs, with a focal point on oncology, steadily reinforcing its pre-clinical pipeline.</span><span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;">  </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Unwavering Investment in Advancing the Platform:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company maintains an unwavering commitment to invest in its platform, continually unlocking the potential of biology through AI and machine learning </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">–</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> the pinnacle of being on the forefront of machine learning advancing algorithms and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In essence, the Company is sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s platform comprises five key components, each playing a crucial role in the discovery and optimization of precision antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing the Company to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. Next, the Company uses its EngageTx T-cell engager platform to create bispecific antibodies. Finally, antibodies are transformed into conditionally activated antibodies by ShieldTx, the Company’s antibody masking technology.  Each layer of the tech stack is designed to work synergistically, enabling the Company to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img alt="Graphic" src="ibio-20231231x10q001.jpg" style="display:inline-block;height:206.15pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Epitope Steering Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company’s epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, the Company can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of its antibody discovery process.  The Company’s AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from naïve or immunized libraries.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Naïve Human Antibody Library</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, the Company has extracted a diverse array of Complementarity-Determining Region (“CDR”) sequences. Subsequently, it has meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from the Company’s library.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">StableHu</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> AI Antibody-Optimizing Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company’s proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EngageTx CD3-Based T-Cell Engager Panel</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized its StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows the Company to pair the panel with a wide variety of tumor-targeting antibodies.  Importantly, the Company was able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to the Company’s StableHu technology, has the ability to reduce the risk of immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 10pt 36pt;">Furthermore, the Company’s StableHu technology enabled it to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ShieldTx</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 10pt 36pt;">The Company has enhanced its proprietary technology with the introduction of ShieldTx, a patent-pending innovative antibody masking technique. ShieldTx leverages the Company's engineered epitope technology, which is utilized not only for the identification of antibodies against complex drug targets but also for concealing the antibodies' active sites. A significant hurdle in therapeutic antibody development is the expression of drug target on both healthy and diseased tissues, leading to adverse effects on non-targeted tissues. ShieldTx is designed to address this challenge by rendering antibodies inactive until they reach a specific environment unique to diseased tissues. Upon contact with this environment, the masking element is detached, activating the antibody. In the tumor microenvironment this is achieved by a highly expressed matrix metalloproteinase. This strategy aims to minimize or eliminate unintended effects on healthy tissues, thereby improving the safety profile and reducing the immunogenicity risks associated with bispecific antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Modalities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Epitope steering, a technology the Company is pioneering, has the potential to positively impact various areas of medicine. In the field of immuno-oncology, it can be used to develop antibodies targeting specific cancer antigens, potentially enhancing the efficacy of treatments like checkpoint inhibitors and CAR-T therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The technology also holds promise in the realm of systemic secreted and cell-surface therapeutics. Epitope steering can be applied to the development of antibodies, circulating immune modulation factors, secreted enzymes, and transmembrane proteins. This could be particularly beneficial in treating diseases such as heart failure, infectious diseases, and rare genetic conditions.  In the context of localized regenerative therapeutics, epitope steering could potentially be used to develop treatments that target specific damaged or diseased tissues. This approach could be particularly beneficial in the treatment of cardiovascular diseases.  Intratumoral immuno-oncology is another area where epitope steering could make a significant impact. It could potentially be used to develop treatments that alter the tumor microenvironment to favor an immune response against tumors, potentially enhancing the efficacy of treatments that use immune-stimulatory proteins.  The potential of epitope steering extends to cancer vaccine development as well. The ability to target specific epitopes could be beneficial in the development of vaccines, particularly those that aim to increase the number and antitumor activity of a patient's T cells.  Finally, epitope steering could be used to develop treatments for a wide range of diseases, including those in the immune-oncology space, immunology, pain, and potentially in vaccine development. This is particularly relevant for complex and hard-to-drug protein structures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Partnerships</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As noted above, one of the three pillars of value creation that structures the Company’s strategic business approach are strategic partnerships.  At the center of such pillar is the Company’s AI Discovery Platform.  In June 2023, the Company entered into a research collaboration with the National Institute of Allergy and Infectious Diseases (“NIAID”), a component of the National Institutes of Health (“NIH”), to investigate the potential of the Company’s patented AI-driven epitope steering platform for the development of a vaccine for Lassa fever, a sometimes fatal viral disease endemic to parts of West Africa.  During the first quarter FY 2024, the Company entered into a collaboration with a partner to license the use of the Company’s AI Discovery Platform to assist such partner with two targets of interest.  During the second quarter FY 2024, the Company entered into a collaboration with a large pharmaceutical company to assist </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">such partner by using the Company’s patented AI-driven epitope steering platform to assist with one "hard to develop" molecule.  The Company continues to seek out opportunities for future collaborations using the Company’s AI Discovery Platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is currently in the process of building and advancing its pipeline. The focus of the Company’s pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging its technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize on the learnings of competitors, the Company’s programs are primarily adopting a fast follower strategy. This approach allows the Company to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img alt="Graphic" src="ibio-20231231x10q002.jpg" style="display:inline-block;height:261.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Immuno-Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IBIO-101</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In August 2021, the Company signed a worldwide exclusive licensing agreement with RubrYc to develop and commercialize RTX-003 (now referred to as IBIO-101), an anti-CD25 mAb. In September 2022, the Company acquired exclusive ownership rights to IBIO-101.  IBIO-101 is a second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (“Treg”) cells to inhibit the growth of solid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Targeting depletion of Treg cells to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 Rα (“IL-2Rα” or “CD25”), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unfortunately, while first-generation mAbs successfully bound CD25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> cells, they also interfered with interleukin-2 [“IL-2”] signaling to T effector (“Teff”) cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company continues to advance its IL-2 sparing anti-CD25 antibody, IBIO-101, and intend moving the program from IND-enabling stage to an IND filing during the calendar year 2025, subject to funding availability. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TROP-2 x CD3 Bispecific</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using its T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. The Company’s bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using EngageTx, the Company’s lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (“IFNg’), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (“TNFa”), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with the Company’s TROP-2 binding arm and a first generation CD3 engager, SP34, its lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">When tested in a humanized mouse model of squamous cell carcinoma, the Company’s lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MUC16</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreatic cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company’s patented epitope steering AI platform, its innovative approach to this challenge allows its new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer.  During its immunization and screening campaign, the Company identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed.  During pre-clinical studies, the Company’s MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells.  After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells. The Company has utilized its EngageTx platform to engineer MUC16 x CD3 bispecific antibodies and has further optimized the molecules to be double-masked on the MUC16 and the CD3 binding arms of the antibody. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EGFRvIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:12pt;text-align:justify;margin:0pt;">EGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer and head and neck cancer but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In the Company’s pursuit of innovative treatments, iBio is exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Leveraging the Company’s patented AI-enabled epitope steering engine, it has specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, iBio has designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company’s hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR.  Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests.  The Company’s lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, its anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CCR8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins. Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body's natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body's immune response against cancer cells, offering a promising avenue for cancer treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It is important to make sure antibodies are fine-tuned to CCR8 and don't mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using the Company’s unique AI-driven technology, it has successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. The Company’s specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, the Company’s CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company’s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show its anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions.  The Company has specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Autoimmune</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PD-1 Agonist</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Programmed cell death protein 1 (“PD-1”) is a pivotal player in the immune system, acting as a type of "off switch" that helps keep the cells from attacking other cells in the body. By agonizing or enhancing the signaling of PD-1, it is possible to temper the immune response, making it particularly valuable in the treatment of autoimmune diseases. In conditions where the immune system mistakenly wages war on the body's own cells, such as in autoimmune diabetes or lupus, therapies that target PD-1 can potentially reduce the severity of these autoimmune reactions. This approach offers a promising avenue for providing relief to patients suffering from these debilitating conditions. The figures below depict the mechanism of action of antagonistic and agonistic PD-1 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio purchased the global rights to a partnership-ready PD-1 agonistic mAb intended to treat serious autoimmune disorders. While the goal in immuno-oncology is to remove immune tolerance towards cancer cells, in autoimmune diseases the opposite is the case, because autoimmune diseases can result from deficits in peripheral and/or central tolerance mechanisms which presents an opportunity for therapeutic intervention. Specifically, agonism or stimulation of inhibitory receptors like PD-1 or CTLA4, which mediate peripheral tolerance is a promising approach to treat autoimmune diseases. Unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists are difficult to find. RubrYc used its AI Discovery Platform to discover PD-1. PD-1 is currently in the late-discovery stage, having undergone extensive screening and <i style="font-style:italic;">in vitro</i> characterization, and the Company anticipates it will be advanced into <i style="font-style:italic;">in vivo</i> models as IBIO-102, in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preclinical studies, the Company’s PD-1 agonists have been evaluated using a primary T-cell assay. Its top-performing molecules showed a significant decrease in the proinflammatory cytokine IL-2 and reduced expression of the T-cell activation marker CD96. Both of these outcomes are indicative of the desired dampening of T-cell activation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p>
CY2022Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2022Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
69
CY2022Q4 ibio Operations Ceased Area Of Land
OperationsCeasedAreaOfLand
130000
CY2023Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4500000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4100000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1300000
CY2022Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2022Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
69
CY2023 ibio Employee Reduction Expenses
EmployeeReductionExpenses
1900000
CY2023 ibio Severance Transitional Period Days
SeveranceTransitionalPeriodDays
60
CY2023Q4 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
3100000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
130000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
22000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
108000
CY2022Q4 ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
2462000
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
307000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
1980000
CY2023Q4 ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
3100000
CY2022Q4 ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
17600000
CY2022Q4 ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
833000
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
3407000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
22875000
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
316000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
223000
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
316000
CY2022Q4 us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
223000
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3723000
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-22990000
us-gaap Disposal Group Including Discontinued Operation Revenue
DisposalGroupIncludingDiscontinuedOperationRevenue
186000
us-gaap Disposal Group Including Discontinued Operation Costs Of Goods Sold
DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
27000
us-gaap Disposal Group Including Discontinued Operation Gross Profit Loss
DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
159000
ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
5524000
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
671000
us-gaap Disposal Group Including Discontinued Operation General And Administrative Expense
DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
5236000
ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
3100000
ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
17600000
ibio Gain On Sale Of Fixed Assets
GainOnSaleOfFixedAssets
-50000
ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
4933000
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
3721000
us-gaap Disposal Group Including Discontinued Operation Operating Expense
DisposalGroupIncludingDiscontinuedOperationOperatingExpense
33293000
us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
674000
us-gaap Disposal Group Including Discontinued Operation Interest Expense
DisposalGroupIncludingDiscontinuedOperationInterestExpense
448000
ibio Discontinued Operations Miscellaneous Expenses Income
DiscontinuedOperationsMiscellaneousExpensesIncome
1000
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
674000
us-gaap Disposal Group Including Discontinued Operation Other Expense
DisposalGroupIncludingDiscontinuedOperationOtherExpense
449000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-4395000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33583000
CY2023Q4 ibio Disposal Group Operating Lease Right Of Use Assets
DisposalGroupOperatingLeaseRightOfUseAssets
1936000
CY2023Q2 ibio Disposal Group Operating Lease Right Of Use Assets
DisposalGroupOperatingLeaseRightOfUseAssets
1941000
CY2023Q4 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
13024000
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
16124000
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
14960000
CY2023Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
18065000
CY2023Q4 ibio Disposal Group Current Liabilities Operating Lease Obligations
DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
1936000
CY2023Q2 ibio Disposal Group Current Liabilities Operating Lease Obligations
DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
1941000
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1936000
CY2023Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1941000
us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
271000
ibio Disposal Group Amortization Of Finance Lease Right Of Use Assets
DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
5000
ibio Disposal Group Amortization Of Finance Lease Right Of Use Assets
DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
20000
us-gaap Capital Expenditure Discontinued Operations
CapitalExpenditureDiscontinuedOperations
1070000
ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
3100000
ibio Tangible Asset Impairment Charges Discontinued Operations
TangibleAssetImpairmentChargesDiscontinuedOperations
17600000
ibio Disposal Group Including Discontinued Operation Inventory Write Down
DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
4933000
ibio Disposal Group Fixed Assets Incurred But Not Yet Paid In Current Period
DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
1542000
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
343000
us-gaap Interest Paid Discontinued Operations
InterestPaidDiscontinuedOperations
187000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p>
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1000000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
204000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
475000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
610000
CY2023Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2023Q4 ibio Percentage Of Collateral Required
PercentageOfCollateralRequired
0.05
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1300000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
3300000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2788000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4301000
CY2022Q4 ibio Equipment Financing Amount Borrowed
EquipmentFinancingAmountBorrowed
500000
CY2022Q4 ibio Lessee Equipment Lease Term Of Contract
LesseeEquipmentLeaseTermOfContract
P36M
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
4060000
CY2023Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
7579000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q4 us-gaap Inventory Net
InventoryNet
0
CY2023Q2 us-gaap Inventory Net
InventoryNet
0
ibio Discontinued Operations Research And Development Expenses
DiscontinuedOperationsResearchAndDevelopmentExpenses
0
CY2021Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
7500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At December 31, 2023 and June 30, 2023, amounts in excess of insured limits were approximately $3.2 million and $6.9 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended December 31, 2023, the Company reported no revenue from continuing operations and discontinued operations. During the three months ended December 31, 2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from two customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the six months ended December 31, 2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations. During the six months ended December 31, 2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from three customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
3200000
CY2023Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6900000
CY2023Q3 us-gaap Proceeds From Sale Of Buildings
ProceedsFromSaleOfBuildings
17250000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
116000
CY2023Q1 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
5100000
CY2021Q3 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
7500000
CY2023Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2022Q4 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
26000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
62000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
339000
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11383
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3603000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2565000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2722000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1967000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4619000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4619000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
729000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
400000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3890000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4219000
CY2023Q4 ibio Fixed Assets Held For Sale
FixedAssetsHeldForSale
13024000
CY2023Q2 ibio Fixed Assets Held For Sale
FixedAssetsHeldForSale
16124000
CY2023 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
17900000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
375000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
385000
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
5003000
CY2023Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
5003000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5378000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5388000
CY2023Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5000
CY2022Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
49000
CY2022Q4 ibio Equipment Financing Lease Imputed Interest Rate
EquipmentFinancingLeaseImputedInterestRate
0.1062
CY2022Q4 ibio Equipment Leasing Monthly Installment Payable
EquipmentLeasingMonthlyInstallmentPayable
16230
CY2023Q4 ibio Equipment Financing Balance
EquipmentFinancingBalance
323000
CY2023Q4 ibio Equipment Financing Interest Incurred
EquipmentFinancingInterestIncurred
9000
CY2022Q4 ibio Equipment Financing Interest Incurred
EquipmentFinancingInterestIncurred
7000
ibio Equipment Financing Interest Incurred
EquipmentFinancingInterestIncurred
19000
ibio Equipment Financing Interest Incurred
EquipmentFinancingInterestIncurred
7000
CY2023Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
194000
CY2023Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
163000
CY2023Q4 us-gaap Contractual Obligation
ContractualObligation
357000
CY2021Q2 ibio Lessor Finance Lease Monthly Rent
LessorFinanceLeaseMonthlyRent
3819
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
68000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
75000
CY2023Q4 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
13000
CY2022Q4 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
16000
CY2023Q4 us-gaap Lease Cost
LeaseCost
81000
CY2022Q4 us-gaap Lease Cost
LeaseCost
91000
CY2023Q4 ibio Financing Cash Flows From Finance Lease Obligation
FinancingCashFlowsFromFinanceLeaseObligation
67000
CY2022Q4 ibio Financing Cash Flows From Finance Lease Obligation
FinancingCashFlowsFromFinanceLeaseObligation
72000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
136000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
88000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
27000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
17000
us-gaap Lease Cost
LeaseCost
163000
us-gaap Lease Cost
LeaseCost
105000
ibio Financing Cash Flows From Finance Lease Obligation
FinancingCashFlowsFromFinanceLeaseObligation
133000
ibio Financing Cash Flows From Finance Lease Obligation
FinancingCashFlowsFromFinanceLeaseObligation
82000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
475000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
610000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
285000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
272000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
205000
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
351000
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M1D
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M1D
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0950
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0950
CY2023Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
320000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
212000
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
532000
CY2021Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11383
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P88M
CY2021Q3 ibio Lessee Operating Lease Monthly Rent
LesseeOperatingLeaseMonthlyRent
51223
CY2021Q3 ibio Lessee Operating Lease Annual Percentage Increase In Base Rent
LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent
0.03
CY2021Q3 us-gaap Tenant Improvements
TenantImprovements
81860
CY2023Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
141000
CY2022Q4 us-gaap Operating Lease Cost
OperatingLeaseCost
140000
CY2023Q4 ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
141000
CY2022Q4 ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
140000
CY2023Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
141000
CY2022Q4 us-gaap Operating Lease Payments
OperatingLeasePayments
140000
CY2023Q4 ibio Operating Cash Flows From Operating Lease Obligation
OperatingCashFlowsFromOperatingLeaseObligation
158000
CY2022Q4 ibio Operating Cash Flows From Operating Lease Obligation
OperatingCashFlowsFromOperatingLeaseObligation
48000
us-gaap Operating Lease Cost
OperatingLeaseCost
282000
us-gaap Operating Lease Cost
OperatingLeaseCost
281000
ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
282000
ibio Total Operating Lease Costs
TotalOperatingLeaseCosts
281000
us-gaap Operating Lease Payments
OperatingLeasePayments
282000
us-gaap Operating Lease Payments
OperatingLeasePayments
281000
ibio Operating Cash Flows From Operating Lease Obligation
OperatingCashFlowsFromOperatingLeaseObligation
313000
ibio Operating Cash Flows From Operating Lease Obligation
OperatingCashFlowsFromOperatingLeaseObligation
51000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
412000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid Year One
LesseeOperatingLeaseImputedInterestToBePaidYearOne
228000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year One
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne
640000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
462000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Two
LesseeOperatingLeaseImputedInterestToBePaidYearTwo
196000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Two
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo
658000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
518000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Three
LesseeOperatingLeaseImputedInterestToBePaidYearThree
161000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Three
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree
679000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
577000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Four
LesseeOperatingLeaseImputedInterestToBePaidYearFour
121000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Four
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour
698000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
643000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid Year Five
LesseeOperatingLeaseImputedInterestToBePaidYearFive
77000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid Year Five
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive
720000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
712000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid After Year Five
LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive
29000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest To Be Paid After Year Five
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive
741000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3324000
CY2023Q4 ibio Lessee Operating Lease Imputed Interest To Be Paid Total
LesseeOperatingLeaseImputedInterestToBePaidTotal
812000
CY2023Q4 ibio Lessee Operating Lease Liability Principal And Imputed Interest
LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest
4136000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2912000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-4488000
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10563000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-9562000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-18100000
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3723000
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-22990000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-4395000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-33583000
CY2023Q4 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-8211000
CY2022Q4 ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-33553000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-13957000
ibio Unconsolidated Gain Loss Attributable To Stockholders
UnconsolidatedGainLossAttributableToStockholders
-51683000
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1856000
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
490000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1525000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
466000
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-2.42
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-21.54
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-6.27
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-38.82
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.00
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-46.89
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-2.88
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-72.03
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.42
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-68.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-110.85
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5378000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
446000
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
454000
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
915000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1215000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2041000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0452
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.5777
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y2M12D
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2023Q4 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
30000
CY2022Q4 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
86000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
79000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
190000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-000934-index-headers.html Edgar Link pending
0001558370-24-000934-index.html Edgar Link pending
0001558370-24-000934.txt Edgar Link pending
0001558370-24-000934-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ibio-20231231.xsd Edgar Link pending
ibio-20231231x10q.htm Edgar Link pending
ibio-20231231x10q001.jpg Edgar Link pending
ibio-20231231x10q002.jpg Edgar Link pending
ibio-20231231x10q003.jpg Edgar Link pending
ibio-20231231x10q004.jpg Edgar Link pending
ibio-20231231xex31d1.htm Edgar Link pending
ibio-20231231xex31d2.htm Edgar Link pending
ibio-20231231xex32d1.htm Edgar Link pending
ibio-20231231xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
ibio-20231231_def.xml Edgar Link unprocessable
ibio-20231231_lab.xml Edgar Link unprocessable
ibio-20231231_pre.xml Edgar Link unprocessable
ibio-20231231x10q_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ibio-20231231_cal.xml Edgar Link unprocessable